Eugene Yang, MD
Cardiovascular Disease · Bellevue, WANPI 1184654782
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,841 of the $30,899 with a category attached, or 73.9%. Genentech, Inc. accounts for 73.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $10,636 and has fallen 97.5% since, to $263 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $2574.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$23K
- Idorsia Pharmaceuticals US Inc$8K
- Abiomed$150
- Amgen$120
- Abbott$113
- Regeneron$107
Across 10 payments — averaging $23,528 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$235K
What the payments were for
- Consulting fees$22,84174%
- Speaking & faculty fees$7,08023%
- Travel & lodging$4892%
- Food & beverage$4892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $22,841 |
| Idorsia Pharmaceuticals US Inc | 2 | $7,569 |
| Abiomed | 1 | $150 |
| Amgen | 1 | $120 |
| Abbott | 1 | $113 |
| Regeneron | 1 | $107 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,899 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 224 | $354,659 |
| JardianceEmpagliflozin | 48 | $76,085 |
| XareltoRivaroxaban | 36 | $59,311 |
| EntrestoSacubitril/Valsartan | 38 | $55,754 |
| Repatha SureclickEvolocumab | 14 | $18,322 |
| Praluent PenAlirocumab | 17 | $12,212 |
| Eplerenone | 34 | $8,010 |
| Metoprolol Succinate | 344 | $6,971 |
| Icosapent Ethyl | 12 | $5,328 |
| Rosuvastatin Calcium | 191 | $4,969 |
| BrilintaTicagrelor | 11 | $4,864 |
| Atorvastatin Calcium | 401 | $4,266 |
| Ezetimibe | 96 | $2,313 |
| Amlodipine Besylate | 244 | $2,088 |
| Flecainide Acetate | 30 | $1,800 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bellevue
- Robert BersinBellevue$657K
- Thomas AmidonBellevue$64K
- Adam ZivinBellevue$23K
- Craig TuohyBellevue$5K
- Ryan YuanBellevue$5K
- Ronnier AvilesBellevue$5K
- James WatsonBellevue$5K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.